Normal levels of ADAMTS13 and factor H are present in the pharmaceutically licensed plasma for transfusion (Octaplas®) and in the universally applicable plasma (Uniplas) in development

Vox Sanguinis

Volumn 92, Issue 3, 2007, Pages 206-212

  Heger, A ^a   Kannicht, C ^b   Romisch J ^a   Svae, T E ^a  

^a Octapharma Pharmazeutika Produktions GmbH   (Austria)

^b Molecular Biochemistry   (Germany)

Author keywords

ADAMTS13; Octaplas ; S D treated plasma; TTP; Uniplas

Indexed keywords

ANTIGEN; COMPLEMENT FACTOR H; VON WILLEBRAND FACTOR; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

ANTIGEN DETECTION; ARTICLE; BLOOD CHEMISTRY; BLOOD GROUP A; BLOOD GROUP AB; BLOOD GROUP B; BLOOD GROUP O; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DIAGNOSTIC KIT; ENZYME LINKED IMMUNOSORBENT ASSAY; EUROPE; FLUORESCENCE RESONANCE ENERGY TRANSFER; HUMAN; IMMUNODIFFUSION; PLASMA TRANSFUSION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; THROMBOTIC THROMBOCYTOPENIC PURPURA; UNITED STATES;

ADAM PROTEINS; BLOOD COMPONENT TRANSFUSION; COMPLEMENT FACTOR H; HEMOLYTIC-UREMIC SYNDROME; HUMANS; PLASMA;

EID: 33847616443     PISSN: 00429007     EISSN: 14230410     Source Type: Journal    
DOI: 10.1111/j.1423-0410.2006.00884.x     Document Type: Article

References (34)

1. Sánches-Corral P, Pérez-Caballero D, Huarte O, Simckes AM, Goicoechea E, López-Trascasa M, Rodríguez de Córdoba S: Structural and functional characterization of factor H mutations associated with atypical hemolytic uremic syndrome. Am J Hum Genet 2002; 71:1285-1295
2. Neumann HPH, Salzmann M, Bohnert-Iwan B, Mannuelian T, Skerka C, Lenk D, Bender BU, Cybulla M, Riegler P, Königsrainer A, Neyer U, Bock A, Widmer U, Male DA, Franke G, Zipfel PF: Haemolytic uraemic syndrome and mutations of the factor H gene: a registry-based study of German speaking countries. J Med Genet 2003; 40:676-681
3. Zheng X, Chung D, Takayama TK, Majerus EM, Sadler JE, Fujikawa K: Structure of von Willebrand factor-cleaving protease (ADAMTS13), a metalloprotease involved in thrombotic thrombocytopenic purpura. J Biol Chem 2001; 276:41059-41063
4. Remuzzi G, Galbusera M, Noris M, Canciani MT, Daina E, Bresin E, Contaretti S, Caprioli J, Gamba S, Ruggenenti P, Perico N, Mannucci PM: von Willebrand factor cleaving protease (ADAMTS13) is deficient in recurrent and familial thrombotic thrombocytopenic purpura and hemolytic uremic sindrome. Blood 2002; 100:778-785
5. Pimanda JE, Chesterman CN, Hogg PJ: A perspective on the measurement of ADAMTS13 in thrombotic thrombocytopaenic purpura. Eur J Haematol 2003; 70:257-262
6. Mayer SA, Aledort LM: Thrombotic microangiopathy: differential diagnosis, pathophysiology and therapeutic strategies. Mt Sinai J Med 2005; 72:166-175
7. Barz D, Budde U, Hellstern P: Therapeutic plasma exchange and plasma infusion in thrombotic microvascular syndromes. Thromb Res 2002; 107:23-27
8. Fontana S, Kremer Hovinga JA, Studt JD, Alberio L, Lämmle B, Taleghani BM: Plasma therapy in thrombotic thrombocytopenic purpura: review of the literature and the Bern experience in a subgroup of patients with severe acquired ADAMTS-13 deficiency. Sem in Haematol 2004; 41:48-59
9. Zheng XL, Kaufman RM, Goodnough LT, Sadler JE: Effect of plasma exchange on plasma ADAMTS13 metalloprotease activity, inhibitor level, and clinical outcome in patients with idiopathic and nonidiopathic thrombotic thrombocytopenic purpura. Blood 2004; 103:4043-4049
10. MacLennan S, Barbara JAJ: Risks and side effects of therapy with plasma and plasma fractions. Baillière's Best Pract Res Clin Haematol 2006; 19:169-189
11. Pelletier JPR, Transue S, Snyder EL: Pathogen inactivation techniques. Baillière's Best Pract Res Clin Haematol 2006; 19:205-242
12. Biesert L, Suhartono H: Solvent/detergent treatment of human plasma - a very robust method for virus inactivation. Validated virus safety of Octaplas. Vox Sang 1998; 74:207-212
13. Solheim BG, Rollag H, Svennevig JL, Arafa O, Fosse E, Bergerud U: Viral safety of solvent/detergent-treated plasma. Transfusion 2000; 40:84-90
14. Hellstern P, Haubelt H: Manufacture and composition of fresh frozen plasma and virus-inactivated therapeutic plasma preparations: correlation between composition and therapeutic efficacy. Thromb Res 2002; 107:3-8
15. Heger A, Römisch J, Svae TE: Stability of solvent/detergent-treated plasma and single-donor fresh-frozen plasma during 48 h after thawing. Transfus Apher Sci 2005; 33:257-267
16. Hellstern P: Solvent/detergent-treated plasma: composition, efficacy, and safety. Curr Opin Hematol 2004; 11:346-350
17. Noddeland H, Töllöfsrud S, Svennevig JL, Bentsen G, Brosstad F, Solheim BG: Universal solvent/detergent-treated fresh frozen plasma (Uniplas) - rationale and clinical properties. Thromb Res 2002; 107:33-37
18. Harrison CN, Lawrie AS, Iobal A, Hunter A, Machin SJ: Plasma exchange with solvent/detergent-treated plasma of resistant thrombotic thrombocytopenic purpura. Br J Haematol 1996; 94:756-758
19. Kentouche K, Budde U, Furlan M, Scharfe V, Schneppenheim R, Zintl F: Remission of thrombotic thrombocytopenic purpura in a patient with compound heterozygous deficiency of von Willebrand factor-cleaving protease by infusion of solvent/detergent plasma. Acta Paediatr 2002; 91:1056-1059
20. Rock G, Clark B, Sutton D, Members of the CAG and CAAN: The Canadian apheresis registry. Transfus Apher Sci 2003; 29:167-177
21. Morfeld F, Schütz R, Josic DJ, Schwinn H: Manufacturing and down-scaling process for a virus-inactivated pooled human plasma. Pharm Ind 1996; 58:433-435
22. Kokame K, Matsumoto M, Fujimura Y, Miyata T: VWF73, a region from D1596 to R1668 of von Willebrand factor, provides a minimal substrate for ADAMTS13. Blood 2004; 103:607-612
23. Kokame K, Nobe Y, Kokubo Y, Okayama A, Miyata T: FRETS-VWF73, a first fluorogenic substrate for ADAMTS13 assay. Br J Haematol 2005; 129:93-100
24. Metzner HJ, Hermentin P, Cuesta-Linker T, Langner S, Müller HG, Friedebold J: Characterization of factor VIII/von Willebrand factor concentrates using a modified method of von Willebrand multimer analysis. Haemophilia 1998; 4:25-32
25. Allford SL, Harrison P, Lawrie AS, Liesner R, MacKie IJ, Machin SJ: Von Willebrand factor-cleaving protease activity in congenital thrombotic thrombocytopenic purpura. Br J Haematol 2000; 111:1215-1222
26. Yarranton H, Lawrie AS, Purdy G, Mackie IJ, Machin SJ: Comparison of von Willebrand factor antigen, von Willebrand factor-cleaving protease and protein S in blood components used for treatment of thrombotic thrombocytopenic purpura. Tranfus Med 2004; 14:39-44
27. Gerritsen HE, Turecek PL, Schwarz HP, Lämmle B, Furlan M: Assay of von Willebrand factor (vWF)-cleaving protease based on decreased collagen binding affinity of degraded vWF: a tool for the diagnosis of thrombotic thrombocytopenic purpura (TTP). Thromb Haemost 1999; 82:1386-1389
28. Mannucci PM, Canciani MT, Forza I, Lussana F, Lattuada A, Rossi E: Changes in health and disease of the metalloprotease that cleaves von Willebrand factor. Blood 2001; 98:2730-2735
29. Rieger M, Ferrari S, Kremer Hoving JA, Konetschny C, Herzog A, Koller L, Webere A, Remuzzi G, Dockal M, Plaimauer B, Scheiflinger F: Relation between ADAMTS13 activity and ADAMTS13 antigen levels in healthy donors and patients with thrombotic microangiopathies (TMA). Thromb Haemost 2006; 95:212-220
30. Miyata T, Kokame K, Banno F: Measurement of ADAMTS13 activity and inhibitors. Curr Opin Hematol 2005; 12:384-389
31. Soejima K, Nakamura H, Hirashima M, Morikawa W, Nozaki C, Nakagaki T: Analysis on the molecular species and concentration of circulating ADAMTS13 in blood. J Biochem 2006; 139:1147-1154
32. Veyradier A, Obert B, Houllier A, Meyer D, Girma JP: Specific von Willebrand factor-cleaving protease in thrombotic microangiopathies: a study of 111 cases. Blood 2001; 98:1765-1772
33. Rock G: A comparison of the two methods for the discrimination of VWF:Ag multimers. Thromb Res 1990; 57:817-824
34. Friese MA, Hellwage J, Jokiranta TS, Meri S, Müller-Quernheim HJ, Peter HH, Eibel H, Zipfel PF: Different regulation of factor H and FHL-1/reconectin by inflammatory mediators and expression of the two proteins in rheumatoid arthritis (RA). Clin Exp Immunol 2000; 121:406-415